A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506241-30-00

Acronym

849-010

Enrollment

199

Registered

2023-12-11

Start date

2021-11-30

Completion date

Unknown

Last updated

2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Colorectal Cancer with KRAS G12C Mutation

Brief summary

Overall Survival (OS), Progression-free Survival (PFS)

Detailed description

Adverse Events, Objective Response Rate (ORR), Duration of Response (DOR), Patient Reported Outcomes (PROs), Quality of Life Assessment

Interventions

DRUGBEVACIZUMAB

DRUGOXALIPLATIN

DRUGErbitux 5 mg/mL solution for infusion

DRUGIRINOTECAN

DRUGRAMUCIRUMAB

DRUGAFLIBERCEPT

DRUGCALCIUM FOLINATE

DRUGFLUOROURACIL

DRUGAdagrasib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS), Progression-free Survival (PFS)	—

Secondary

Measure	Time frame
Adverse Events, Objective Response Rate (ORR), Duration of Response (DOR), Patient Reported Outcomes (PROs), Quality of Life Assessment	—

Countries

Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Portugal, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026